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Prosultiamine treatment as a new therapeutic strategy in human T
lymphotropic virus type I-associated myelopathy/tropical spastic
paraparesis
Human T lymphotropic virus type I (HTLV-I)-associ-
ated myelopathy/tropical spastic paraparesis (HAM/
TSP) is a chronic myelopathy characterized by motor
dysfunction of the lower extremities and urinary dis-
turbance.1 The primary neuropathological feature of
HAM/TSP is chronic inflammation in the spinal cord
caused by high HTLV-I proviral load in peripheral
blood mononuclear cells (PBMC). Therefore, immu-
nomodulatory therapy, such as corticosteroid hor-
mones and interferon-a, has been the main
treatment for HAM/TSP patients.2 However, there
are many issues in long-term treatment with these
drugs, such as insufficient effects and various side-
effects. Once the myelopathy develops, the main
neurological symptoms, such as motor dysfunction
of the lower extremities accompanied by urinary dis-
turbance, are progressive and lead to a deterioration
in the quality of life of patients. Therefore, novel
and safe therapeutic regimens are urgently required
for HAM/TSP patients to use as a treatment, or pre-
vent disease progression.
Prosultiamine (Alinamin), a vitamin B1 derivative,
is safely available in Japan for the treatment of Wer-
nicke’s encephalopathy and polyneuropathy induced
by deficiency of vitamin B1. Based on the data that
prosultiamine can induce the caspase-dependent
apoptosis of HTLV-I-infected cells through disruption
of intracellular redox reactions by a disulfide moiety
in its structure,3 we carried out a clinical trial with
prosultiamine for 24 HAM/TSP patients using an
open-labeled design. Here, I will show the remark-
able efficacy of prosultiamine treatment against
HAM/TSP patients without serious adverse effects.4,5
Prosultiamine 300 mg was given orally once daily
for 12 weeks. As a result, improvement in the motor
function of the lower extremities based on a reduc-
tion in spasticity (e.g. decrease in time required for
walking and descending a flight of stairs) was
observed. Interestingly, this treatment induced the
striking amelioration of urinary disturbance. In an
urodynamic study (UDS), bladder capacity and
detrusor pressure, and then maximum flow rate,
increased significantly. Detrusor overactivity and
detrusor-sphincter dyssynergia improved in 68.8%
and 45.5% of patients, respectively. Improvement in
UDS corresponded with improvements in the score
of nocturia quality of life questionnaire. Thus, given
that the mean duration of illness of the patients
enrolled in the present study was relatively long
(approximately 21 years), the efficacy of this treat-
ment is promising.
In the present study, HTLV-I proviral copy numbers
in PBMC decreased significantly (approximately
15.4%) compared with pretreatment levels. However,
the remarkable clinical improvement in the present
study cannot be attributed solely to a decrease in
HTLV-I proviral copy numbers in PBMC. Although
the exact mechanism is not known, it might be con-
ceivable that, as one of the mechanisms, prosulti-
amine functions to induce the apoptosis of HTLV-I-
infected cells by the disruption of intracellular redox
system in the spinal cord, even if the extent of reduc-
tion of the number of HTLV-I-infected cells in PBMC
is relatively small. Further investigations including
analysis of cerebrospinal fluid are required to eluci-
date the exact mechanism of action of prosultiamine.
Overall, the present results suggest that prosulti-
amine could be a new promising therapeutic tool for
HAM/TSP patients. Therefore, further studies are
warranted for the evaluation of prosultiamine treat-
ment against HAM/TSP in a large-scale, randomized,
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